Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders

Stress

Volumn 12, Issue 2, 2009, Pages 97-114

  Smith, Karen L ^a   Jessop, David S ^b   Finn, David P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

5 HT; Depression; Hypothalamo pituitary adrenal axis; Imidazoline binding sites; Monoamine neurones; Noradrenaline; Sympathetic nervous system

Indexed keywords

2 (2 IMIDAZOLIN 2 YL)QUINOLINE; AGMATINE; ANTAZOLINE; CIRAZOLINE; CLONIDINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DIZOCILPINE; EFAROXAN; GLUCOCORTICOID; GUANIDINE DERIVATIVE; HARMAN; HYDROCORTISONE; IDAZOXAN; IMIDAZOLINE; IODINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOXONIDINE; RILMENIDINE; YOHIMBINE;

ANIMAL BEHAVIOR; ANXIETY DISORDER; BEHAVIOR CHANGE; BIPOLAR DISORDER; BRAIN REGION; CAT; CATECHOLAMINERGIC SYSTEM; CHRONIC INFLAMMATION; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG POTENTIATION; FORCED SWIMMING TEST; HORSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOBLOTTING; MAZE TEST; MEDULLA OBLONGATA; MENTAL DEFICIENCY; NEUROENDOCRINE SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; PANIC; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; RODENT; SEROTONINERGIC SYSTEM; STRESS; SUICIDE;

ANIMALS; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMIDAZOLES; IMIDAZOLINE RECEPTORS; NEURONS; NOREPINEPHRINE; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 61349192575     PISSN: 10253890     EISSN: 16078888     Source Type: Journal    
DOI: 10.1080/10253890802302908     Document Type: Review

References (219)

1. Abu Ghazaleh H, Lalies MD, Husbands SM, Nutt DJ, Hudson AL. 2007. The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. Neurosci Lett 422:109-113.
2. Adell A, Biggs TA, Myers RD. 1996. Action of harman (1-methyl-beta- carboline) on the brain: Body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 35:1101-1107.
3. Alahari SK, Lee JW, Juliano RL. 2000. Nischarin, a novel protein that interacts with the integrin alpha 5 subunit and inhibits cell migration. J Cell Biol 151:1141-1154.
4. Alahari SK. 2003. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res 288:415-424.
5. Albores R, Neafsey EJ, Drucker G, Fields JZ, Collins MA. 1990. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc Natl Acad Sci USA 87:9368-9372.
6. Alexander SL, Irvine CH. 2000. The effect of the alpha-2-adrenergic agonist, clonidine, on secretion patterns and rates of adrenocorticotropic hormone and its secretagogues in the horse. J Neuroendocrinol 12:874-880.
7. Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. 2006. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem 96:1551-1559.
8. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
9. Aricioglu F, Altunbas H. 2003. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann N Y Acad Sci 1009:196-201.
10. Atlas D. 1994. Identifying clonidine-displacing substance. Science 266:462-464.
11. Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD, Jr. 1999. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 156:585-588.
12. Ballesteros J, Maeztu AI, Callado LF, Meana JJ, Gutierrez M. 2008. Specific binding of [(3)H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. Eur Neuropsychopharmacol 18:55-61.
13. Banki CM, Karmacsi L, Bissette G, Nemeroff CB. 1992. CSF corticotropin-releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 2:107-113.
14. Bissette G, Klimek V, Pan J, Stockmeier C, Ordway G. 2003. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 28:1328-1335.
15. + channel-blocking compounds. Diabetes 53(3):S135-S139.
16. Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP. 2008. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab 19:175-180.
17. Bousquet P, Feldman J, Schwartz J. 1984. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 230:232-236.
18. Bousquet P, Feldman J, Atlas D. 1986. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol 124:167-170.
19. Bousquet P, Greney H, Bruban V, Schann S, Ehrhardt JD, Monassier L, Feldman J. 2003. I(1) imidazoline receptors involved in cardiovascular regulation: Where are we and where are we going? Ann NY Acad Sci 1009:228-233.
20. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS. 1997. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 154:624-629.
21. Brown CM, MacKinnon AC, Redfern WS, Williams A, Linton C, Stewart M, Clague RU, Clark R, Spedding M. 1995. RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Br J Pharmacol 116:1737-1744.
22. Burke SL, Malpas SC, Head GA. 1998. Effect of rilmenidine on the cadiovascular responses to stress in the conscious rabbit. J Auton Nerv Syst 72:177-186.
23. Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, Gold PW, Chrousos GP. 1990. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 126:1888-1894.
24. Campbell WR, Potter DE. 1994. Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics. J Ocul Pharmacol 10:393-402.
25. Carpenter WT, Jr, Bunney WE, Jr. 1971. Behavioral effects of cortisol in man. Semin Psychiatry 3:421-434.
26. Chalmers J, Pilowsky P. 1991. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens 9:675-694.
27. Chan SL, Morgan NG. 1990. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur J Pharmacol 176:97-101.
28. Christiansen L, Tan Q, Iachina M, Bathum L, Kruse TA, McGue M, Christensen K. 2007. Candidate gene polymorphisms in the serotonergic pathway: Influence on depression symptomatology in an elderly population. Biol Psychiatry 61:223-230.
29. Chrousos GP, Gold PW. 1992. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. Jama 267:1244-1252.
30. Cohen H, Zohar J, Gidron Y, Matar MA, Belkind D, Loewenthal U, Kozlovsky N, Kaplan Z. 2006. Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol Psychiatry 59:1208-1218.
31. Connor TJ, Kelly JP, Leonard BE. 1997. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. Pharmacol Biochem Behav 58:961-967.
32. Cooper EJ, Hudson AL, Parker CA, Morgan NG. 2003. Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans. Eur J Pharmacol 482:189-196.
33. Crowley GM. 1964. The enzymatic synthesis of 5′- phosphoribosylimidazoleacetic acid. J Biol Chem 239:2593-2601.
34. Cummings S, Hinds D, Young WS, 3rd. 1994. Corticotropin-releasing factor mRNA increases in the inferior olivary complex during harmaline-induced tremor. Brain Res 660:199-208.
35. Dardonville C, Rozas I. 2004. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med Res Rev 24:639-661.
36. Day R, Nielsen JA, Korten A, Ernberg G, Dube KC, Gebhart J, Jablensky A, Leon C, Marsella A, Olatawura M et al. 1987. Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization. Cult Med Psychiatry 11:123-205.
37. De Bellis MD, Gold PW, Geracioti TD, Jr, Listwak SJ, Kling MA. 1993. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150:656-657.
38. Diaz A, Mayet S, Dickenson AH. 1997. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur J Pharmacol 333:9-15.
39. Dubrovsky B. 2000. The specificity of stress responses to different nocuous stimuli: Neurosteroids and depression. Brain Res Bull 51:443-455.
40. Durden DA, Nguyen TV, Boulton AA. 1988. Kinetics of intraventricularly injected trace amines and their deuterated isotopomers. Neurochem Res 13:943-950.
41. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. 2001. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 79:931-940.
42. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. 1998. Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci 19:381-390.
43. Ergene E, Schoener EP. 1993. Effects of harmane (1-methyl-beta-carboline) on neurons in the nucleus accumbens of the rat. Pharmacol Biochem Behav 44:951-957.
44. Ernsberger P. 1998. Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1-imidazoline receptors. J Auton Nerv Syst 72:147-154.
45. Ernsberger P, Haxhiu MA. 1997. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 273:R1572-R1579.
46. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. 1993. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 264:172-182.
47. Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG. 1995. I1-imiddazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann NY Acad Sci 763:22-42.
48. Escriba PV, Sastre M, Wang H, Regunathan S, Reis DJ, Garcia-Sevilla JA. 1994. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci Lett 178:81-84.
49. Esler M, Lux A, Jennings G, Hastings J, Socratous F, Lambert G. 2004. Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion. Arch Mal Coeur Vaiss 97:786-792.
50. Fauvel JP, Najem R, Ryon B, Ducher M, Laville M. 1999. Effects of rilmenidine on stress-induced peak blood pressure and renal function. J Cardiovasc Pharmacol 34:41-45.
51. Felsen D, Ernsberger P, Meeley MP, Reis DJ. 1987. Clonidine displacing substance is biologically active on smooth muscle. Eur J Pharmacol 142:453-455.
52. Fernandes JF, Castellani O, Plese M. 1960. Biosynthesis of histamine ribotide and imidazoleacetate ribotide. Biochem Biophys Res Commun 3:679-684.
53. Finlay-Jones R, Brown GW. 1981. Types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med 11:803-815.
54. Finn DP, Lalies MD, Harbuz MS, Jessop DS, Hudson AL, Nutt DJ. 2002. Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. Neuropharmacology 42:958-965.
55. Finn DP, Marti O, Harbuz MS, Valles A, Belda X, Marquez C, Jessop DS, Lalies MD, Armario A, Nutt DJ, Hudson AL. 2003. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 167:195-202.
56. Finn DP, Hudson AL, Kinoshita H, Coventry TL, Jessop DS, Nutt DJ, Harbuz MS. 2004. Imidazoline 2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic-pituitary-adrenal axis activity in control and acute restraint stressed rats. J Psychopharmacol 18:47-53.
57. Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB. 1996. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 39:703-707.
58. Friedrich VL, Jr, Martinelli GP, Prell GD, Holstein GR. 2007. Distribution and cellular localization of imidazoleacetic acid-ribotide, an endogenous ligand at imidazol(in)e and adrenergic receptors, in rat brain. J Chem Neuroanat 33:53-64.
59. Garcia-Sevilla JA, Escriba PV, Guimon J. 1999. Imidazoline receptors and human brain disorders. Ann NY Acad Sci 881:392-409.
60. Garcia-Sevilla JA, Escriba PV, Sastre M, Walzer C, Busquets X, Jaquet G, Reis DJ, Guimon J. 1996. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry 53:803-810.
61. Ghadirian AM, Marcovitz S, Pearson Murphy BE. 2005. A case of seasonal bipolar disorder exacerbated by Cushing's disease. Compr Psychiatry 46:155-158.
62. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BE. 1995. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 37:369-375.
63. Gibbons JL, McHugh Pr. 1962. Plasma cortisol in depressive illness. J Psychiatr Res 1:162-171.
64. Giraldi T, De Vanna M, Malagoli M, Tuveri G, Sutto K, Schillani G, Grassi L. 2007. Mental adaptation to cancer: Depression and blood platelet monoamine oxidase activity in breast cancer patients. Anticancer Res 27:1715-1719.
65. Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M, Smith C, Egan C, Davis K, Mattson MV. 2000. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 60:121-132.
66. Glue P, Wilson S, Campling GM, Knightly M, Franklin M, Cowen PJ, Nutt DJ. 1992. Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: Preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology 17:261-266.
67. +-channels in mediating the elevations of cerebral blood flow and arterial pressure by hypoxic stimulation of oxygen-sensitive neurons of rostral ventrolateral medulla. Brain Res 827:210-214.
68. Gollan JK, Lee R, Coccaro EF. 2005. Developmental psychopathology and neurobiology of aggression. Dev Psychopathol 17:1151-1171.
69. Gong ZH, Li YF, Zhao N, Yang HJ, Su RB, Luo ZP, Li J. 2006. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol 550:112-116.
70. Gothert M, Molderings GJ, Fink K, Schlicker E. 1995. Alpha 2-adrenoceptor-independent inhibition by imidazolines and guanidines of noradrenaline release from peripheral, but not central noradrenergic neurons. Ann NY Acad Sci 763:405-419.
71. Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. 1983. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 40:493-500.
72. Grigoriadis DE. 2005. The corticotropin-releasing factor receptor: A novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 9:651-684.
73. Gruen R, Baron M. 1984. Stressful life events and schizophrenia. Relation to illness onset and family history. Neuropsychobiology 12:206-208.
74. Halaris A, Piletz JE. 2001. Imidazoline receptors: Possible involvement in the pathophysiology and treatment of depression. Hum Psychopharmacol 16:65-69.
75. Halaris A, Piletz JE. 2003. Relevance of imidazoline receptors and agmatine to psychiatry: A decade of progress. Ann NY Acad Sci 1009:1-20.
76. Halaris A, Zhu H, Ali J, Nasrallah A, Lindsay De Vane C, Piletz JE. 2002. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. Int J Neuropsychopharmacol 5:37-46.
77. Head GA, Burke SL. 2004. Sympathetic responses to stress and rilmenidine in 2K1C rabbits: Evidence of enhanced nonvascular effector mechanism. Hypertension 43:636-642.
78. Heim C, Plotsky PM, Nemeroff CB. 2004. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 29:641-648.
79. Herraiz T, Chaparro C. 2005. Human monoamine oxidase is inhibited by tobacco smoke: Beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326:378-386.
80. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
81. Holt A, Wieland B, Baker GB. 2004. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br J Pharmacol 143:495-507.
82. Hudson CJ, Young LT, Li PP, Warsh JJ. 1993. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13:278-293.
83. Hudson AL, Chapleo CB, Lewis JW, Husbands S, Grivas K, Mallard NJ, Nutt DJ. 1997. Identification of ligands selective for central I2-imidazoline binding sites. Neurochem Int 30:47-53.
84. Hudson AL, Gough R, Tyacke R, Lione L, Lalies M, Lewis J, Husbands S, Knight P, Murray F, Hutson P, Nutt DJ. 1999. Novel selective compounds for the investigation of imidazoline receptors. Ann NY Acad Sci 881:81-91.
85. Ising M, Holsboer F. 2007. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. Exp Clin Psychopharmacol 15:519-528.
86. Isolan LR, Zeni CP, Mezzomo K, Blaya C, Kipper L, Heldt E, Manfro GG. 2005. Behavioral inhibition and history of childhood anxiety disorders in Brazilian adult patients with panic disorder and social anxiety disorder. Rev Bras Psiquiatr 27:97-100.
87. Ivanov TR, Zhu H, Regunathan S, Reis DJ, Dontenwill M, Vonthron C, Bousquet P, Piletz JE. 1998. Co-detection by two imidazoline receptor protein antisera of a novel 85 kilodalton protein. Biochem Pharmacol 55:649-655.
88. Joca SR, Ferreira FR, Guimaraes FS. 2007. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 10:227-249.
89. Jolkkonen J, Lepola U, Bissette G, Nemeroff C, Riekkinen P. 1993. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 33:136-138.
90. Jope RS, Williams MB. 1994. Lithium and brain signal transduction systems. Biochem Pharmacol 47:429-441.
91. Judge SJ, Ingram CD, Gartside SE. 2004. Moderate differences in circulating corticosterone alter receptor-mediated regulation of 5-hydroxytryptamine neuronal activity. J Psychopharmacol 18:475-483.
92. Kageyama K, Tozawa F, Horiba N, Watanobe H, Suda T. 1998. Serotonin stimulates corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Neurosci Lett 243:17-20.
93. Kalin NH, Shelton SE, Turner JG. 1992. Effects of beta-carboline on fear-related behavioral and neurohormonal responses in infant rhesus monkeys. Biol Psychiatry 31:1008-1019.
94. Kendler KS, Karkowski-Shuman L. 1997. Stressful life events and genetic liability to major depression: Genetic control of exposure to the environment? Psychol Med 27:539-547.
95. Kendler KS, Karkowski LM, Prescott CA. 1999. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 156:837-841.
96. Kim H, Sablin SO, Ramsay RR. 1997. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337:137-142.
97. King PR, Gundlach AL, Louis WJ. 1995. Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine. Brain Res 675:264-278.
98. de Kloet CS, Vermetten E, Heijnen CJ, Geuze E, Lentjes EG, Westenberg HG. 2007. Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology 32:215-226.
99. de Kloet CS, Vermetten E, Geuze E, Lentjes EG, Heijnen CJ, Stalla GK, Westenberg HG. 2008. Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. Prog Brain Res 167:287-291.
100. Krishnan KR, Doraiswamy PM, Lurie SN, Figiel GS, Husain MM, Boyko OB, Ellinwood EH, Jr, Nemeroff CB. 1991. Pituitary size in depression. J Clin Endocrinol Metab 72:256-259.
101. Lahniers CE, White K. 1976. Changes in environmental life events and their relationship to psychiatric hospital admissions. J Nerv Ment Dis 163:154-158.
102. Laubie M, Poignant JC, Scuvee-Moreau J, Dabire H, Dresse A, Schmitt H. 1985. Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist. J Pharmacol 16:259-278.
103. Lavinsky D, Arteni NS, Netto CA. 2003. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 141:19-24.
104. Li D, He L. 2007. Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia. Am J Med Genet B Neuropsychiatr Genet.
105. Lione LA, Nutt DJ, Hudson AL. 1998. Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: A selective ligand for imidazoline I2 receptors. Eur J Pharmacol 353:123-135.
106. Liposits Z, Uht RM, Harrison RW, Gibbs FP, Paull WK, Bohn MC. 1987. Ultrastructural localization of glucocorticoid receptor (GR) in hypothalamic paraventricular neurons synthesizing corticotropin releasing factor (CRF). Histochemistry 87:407-412.
107. Li YF, Gong ZH, Cao JB, Wang HL, Luo ZP, Li J. 2003. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 469:81-88.
108. MacInnes N, Handley SL. 2005. Autoradiographic localisation of [3H]2-BFI imidazoline I2 binding sites in mouse brain. Eur J Pharmacol 516:139-144.
109. MacKinnon AC, Redfern WS, Brown CM. 1995. [3H]-RS-45041-190: A selective high-affinity radioligand for I2 imidazoline receptors. Br J Pharmacol 116:1729-1736.
110. Manji HK. 1992. G proteins: Implications for psychiatry. Am J Psychiatry 149:746-760.
111. Marti O, Armario A. 1998. Anterior pituitary response to stress: Time-related changes and adaptation. Int J Dev Neurosci 16:241-260.
112. Mayer KH, Stamler J, Dyer A, Freinkel N, Stamler R, Berkson DM, Farber B. 1976. Epidemiologic findings on the relationship of time of day and time since last meal to glucose tolerance. Diabetes 25:936-943.
113. McEwen BS. 2007. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873-904.
114. Meana JJ, Herrera-Marschitz M, Goiny M, Silveira R. 1997. Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain. Brain Res 744:216-226.
115. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. 2004. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24:1478-1485.
116. Mest HJ, Raap A, Schloos J, Treinies I, Paal M, Giese U, Koivisto V. 2001. Glucose-induced insulin secretion is potentiated by a new imidazoline compound. Naunyn Schmiedebergs Arch Pharmacol 364:47-52.
117. Michelson D, Galliven E, Hill L, Demitrack M, Chrousos G, Gold P. 1997. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 82:2601-2606.
118. Modell S, Yassouridis A, Huber J, Holsboer F. 1997. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65:216-222.
119. Molderings GJ, Likungu J, Jakschik J, Gothert M. 1997. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues. Br J Pharmacol 122:43-50.
120. Morgan NG, Chan SL. 2001. Imidazoline binding sites in the endocrine pancreas: Can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 7:1413-1431.
121. Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. 1999. Imidazolines and pancreatic hormone secretion. Ann NY Acad Sci 881:217-228.
122. Mourtada M, Smith SA, Morgan NG. 1997. Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans. Biochem Biophys Res Commun 236:162-166.
123. Muller WE, Fehske KJ, Borbe HO, Wollert U, Nanz C, Rommelspacher H. 1981. On the neuropharmacology of harmane and other beta-carbolines. Pharmacol Biochem Behav 14:693-699.
124. Munoz-Hoyos A, Fernandez-Garcia JM, Molina-Carballo A, Macias M, Escames G, Ruiz-Cosano C, Acuna-Castroviejo D. 2000. Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 29:48-53.
125. Musgrave IF, Badoer E. 2000. Harmane produces hypotension following microinjection into the RVLM: Possible role of I(1)-imidazoline receptors. Br J Pharmacol 129:1057-1059.
126. Nash MW, Sugden K, Huezo-Diaz P, Williamson R, Sterne A, Purcell S, Sham PC, Craig IW. 2005. Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. Am J Med Genet B Neuropsychiatr Genet 135:33-37.
127. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. 1988. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577-579.
128. Nutt DJ, French N, Handley S, Hudson A, Husbands S, Jackson H, Jordan S, Lalies MD, Lewis J, Lione L, et al. 1995. Functional studies of specific imidazoline-2 receptor ligands. Ann NY Acad Sci 763:125-139.
129. Nutt DJ, Lalies MD, Lione LA, Hudson AL. 1997. Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 11:163-168.
130. O'Neill MF, Osborne DJ, Woodhouse SM, Conway MW. 2001. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J Psychopharmacol 15:18-22.
131. Olmos G, Gabilondo AM, Miralles A, Escriba PV, Garcia-Sevilla JA. 1993. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Br J Pharmacol 108:597-603.
132. Olmos G, Alemany R, Boronat MA, Garcia-Sevilla JA. 1999. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Ann NY Acad Sci 881:144-160.
133. Pacak K. 2000. Stressor-specific activation of the hypothalamic- pituitary-adrenocortical axis. Physiol Res 49(Suppl 1):S11-S17.
134. Pacak K, Palkovits M. 2001. Stressor specificity of central neuroendocrine responses: Implications for stress-related disorders. Endocr Rev 22:502-548.
135. Pacheco MA, Stockmeier C, Meltzer HY, Overholser JC, Dilley GE, Jope RS. 1996. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 723:37-45.
136. Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J, Kerwin RW, Lightman S. 2004. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) 177:200-206.
137. Parini A, Moudanos CG, Pizzinat N, Lanier SM. 1996. The elusive family of imidazoline binding sites. Trends Pharmacol Sci 17:13-16.
138. Parker CA, Hudson AL, Nutt DJ, Dillon MP, Eglen RM, Crosby J. 2000. Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells. Eur J Pharmacol 387:27-30.
139. Parker KJ, Schatzberg AF, Lyons DM. 2003. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 43:60-66.
140. Parker CA, Anderson NJ, Robinson ES, Price R, Tyacke RJ, Husbands SM, Dillon MP, Eglen RM, Hudson AL, Nutt DJ, Crump MP, Crosby J. 2004. Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 43:16385-16392.
141. Paterson, L.M., Tyacke, R.J., Robinson, E.S., Nutt, D.J., and Hudson, A.L. 2006. In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I(2) binding in relation to MAO: Evidence for two distinct I(2) binding sites. Neuropharmacology 52:395-404.
142. Piletz J, Baker R, Halaris A. 2008. Platelet imidazoline receptors as state marker of depressive symptomatology. J Psychiatr Res 42:41-49.
143. Piletz JE, Halaris A, Saran A, Marler MR. 1991. Desipramine lowers tritiated para-aminoclonidine binding in platelets of depressed patients. Arch Gen Psychiatry 48:813-820.
144. Piletz JE, Halaris A, Ernsberger PR. 1994. Psychopharmacology of imidazoline and alpha 2-adrenergic receptors: Implications for depression. Crit Rev Neurobiol 9:29-66.
145. Piletz JE, Halaris A, Nelson J, Qu Y, Bari M. 1996a. Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J Psychiatr Res 30:147-168.
146. Piletz JE, Halaris AE, Chikkala D, Qu Y. 1996b. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res 30:169-184.
147. Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, Baldwin J, Reis DJ. 2000. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol 19:319-329.
148. Pineda J, Ugedo L, Garcia-Sevilla JA. 1993. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: Possible involvement of imidazoline-preferring receptors. Naunyn Schmiedebergs Arch Pharmacol 348:134-140.
149. Plotsky PM. 1987. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 121:924-930.
150. Popma A, Doreleijers TA, Jansen LM, Van Goozen SH, Van Engeland H, Vermeiren R. 2007. The diurnal cortisol cycle in delinquent male adolescents and normal controls. Neuropsychopharmacology 32:1622-1628.
151. Prell GD, Martinelli GP, Holstein GR, Matulic-Adamic J, Watanabe KA, Chan SL, Morgan NG, Haxhiu MA, Ernsberger P. 2004. Imidazoleacetic acid-ribotide: An endogenous ligand that stimulates imidazol(in)e receptors. Proc Natl Acad Sci USA 101:13677-13682.
152. Raddatz R, Parini A, Lanier SM. 1995. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J Biol Chem 270:27961-27968.
153. Reddig PJ, Xu D, Juliano RL. 2005. Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin. J Biol Chem 280:30994-31002.
154. Regunathan S, Meeley MP, Reis DJ. 1991. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol Pharmacol 40:884-888.
155. Reis DJ, Regunathan S. 2000. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21:187-193.
156. Reis DJ, Piletz JE. 1997. The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am J Physiol 273:R1569-R1571.
157. Renouard A, Widdowson PS, Cordi A. 1993. [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: Pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 109:625-631.
158. Ribeiro SC, Tandon R, Grunhaus L, Greden JF. 1993. The DST as a predictor of outcome in depression: A meta-analysis. Am J Psychiatry 150:1618-1629.
159. Robinson ES, Tyacke RJ, Nutt DJ, Hudson AL. 2002. Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. Eur J Pharmacol 450:55-60.
160. Rommelspacher H, May T, Salewski B. 1994. Harman (1-methyl-beta- carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol 252:51-59.
161. Rubin RT, Phillips JJ, McCracken JT, Sadow TF. 1996. Adrenal gland volume in major depression: Relationship to basal and stimulated pituitary-adrenal cortical axis function. Biol Psychiatry 40:89-97.
162. Ruiz-Durantez E, Ruiz-Ortega JA, Pineda J, Ugedo L. 2001. Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci Lett 308:197-200.
163. Ruiz-Ortega JA, Ugedo L. 1997. The stimulatory effect of clonidine on locus coeruleus neurons of rats with inactivated alpha 2-adrenoceptors: Involvement of imidazoline receptors located in the nucleus paragigantocellularis. Naunyn Schmiedebergs Arch Pharmacol 355:288-294.
164. Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. 2000. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmocol 130:146-152.
165. Samad N, Perveen T, Haider S, Haleem MA, Haleem DJ. 2006. Inhibition of restraint-induced neuroendocrine and serotonergic responses by buspirone in rats. Pharmacol Rep 58:636-642.
166. Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. 2002. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem 277:19439-19447.
167. Saphier D, Feldman S. 1989. Catecholaminergic projections to tuberoinfundibular neurones of the paraventricular nucleus: II. Effects of stimulation of the ventral noradrenergic ascending bundle: Evidence for cotransmission. Brain Res Bull 23:397-404.
168. Saphier D, Welch JE. 1994. Central stimulation of adrenocortical secretion by 5-hydroxytryptamine1 A agonists is mediated by sympathomedullary activation. J Pharmacol Exp Ther 270:905-917.
169. Saphier D, Farrar GE, Welch JE. 1995. Differential inhibition of stress-induced adrenocortical responses by 5-HT1A agonists and by 5-HT2 and 5-HT3 antagonists. Psychoneuroendocrinology 20:239-257.
170. Sapolsky RM, Romero LM, Munck AU. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55-89.
171. Sastre-Coll A, Esteban S, Miralles A, Zanetti R, Garcia-Sevilla JA. 2001. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo. Neurosci Lett 301:29-32.
172. Sastre M, Escriba PV, Reis DJ, Garcia-Sevilla JA. 1995. Decreased number and immunoreactivity of I2-imidazoline receptors in the frontal cortex of suicide victims. Ann NY Acad Sci 763:520-522.
173. Sautter FJ, Bissette G, Wiley J, Manguno-Mire G, Schoenbachler B, Myers L, Johnson JE, Cerbone A, Malaspina D. 2003. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 54:1382-1388.
174. Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A, Rothenhausler HB, Krauseneck T, Nollert G, Kapfhammer HP. 2004. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: A randomized study. Biol Psychiatry 55:627-633.
175. Schmidt U, Frerick H, Kraft K, Schenk N, Löw-Kröger A. 1992. Hypertension: A possible risk in road traffic. J Cardiovasc Pharmacol 20:S50-S56.
176. Scott LV, Dinan TG. 1998. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: Implications for the pathophysiology of depression. Life Sci 62:1985-1998.
177. Separovic D, Kester M, Ernsberger P. 1996. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 49:668-675.
178. Separovic D, Kester M, Haxhiu MA, Ernsberger P. 1997. Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 749:335-339.
179. Silverman AJ, Hou-Yu A, Chen WP. 1989. Corticotropin-releasing factor synapses within the paraventricular nucleus of the hypothalamus. Neuroendocrinology 49:291-299.
180. Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM, Kagan J, Snidman N, Faraone SV, Hirshfeld-Becker D, Tsuang MT, Slaugenhaupt SA, Rosenbaum JF, Sklar PB. 2005. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 57:1485-1492.
181. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ. 2006. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103:5585-5590.
182. Squires PE, Hills CE, Rogers GJ, Garland P, Farley SR, Morgan NG. 2004. The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilisation in pancreatic beta-cells. Eur J Pharmacol 501:31-39.
183. Sun Z, Chang CH, Ernsberger P. 2007. Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells. J Neurochem 101:99-108.
184. Swanson LW, Sawchenko PE, Rivier J, Vale WW. 1983. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 36:165-186.
185. Szabo B, Urban R. 1995. Mechanism of sympathoinhibition by imidazolines. Ann NY Acad Sci 763:552-565.
186. Szabo B. 2002. Imidazoline antihypertensive drugs: A critical review on their mechanism of action. Pharmacol Ther 93:1-35.
187. Takada K, Hayashi Y, Kamibayashi T, Mammoto T, Yamatodani A, Kitamura S, Yoshiya I. 1997. The involvement of pertussis toxin-sensitive G proteins in the post receptor mechanism of central I1-imidazoline receptors. Br J Pharmacol 120:1575-1581.
188. Talalaenko AN, Krivobok GK, Pankrat'ev DV, Goncharenko NV. 2006. Neurochemical mechanisms of the dorsal pallidum in the antiaversive effects of anxiolytics in various models of anxiety. Neurosci Behav Physiol 36:749-754.
189. Teixeira de Castro RR, Tibirica E, de Oliveira MA, Moreira PB, Catelli MF, Rocha MN, Nobrega AC. 2006. Reduced hemodynamic responses to physical and mental stress under low-dose rilmenidine in healthy subjects. Cardiovasc Drugs Ther 20:129-134.
190. Tesson F, Limon-Boulez I, Urban P, Puype M, Vandekerckhove J, Coupry I, Pompon D, Parini A. 1995. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem 270:9856-9861.
191. Thomas B, Prell GD. 1995. Imidazoleacetic acid, a gamma-aminobutyric acid receptor agonist, can be formed in rat brain by oxidation of histamine. J Neurochem 65:818-826.
192. Thomson F, Craighead M. 2007. Innovative approaches for the treatment of depression: Targeting the HPA axis. Neurochem Res.
193. Tibirica E, Mermet C, Feldman J, Gonon F, Bousquet P. 1989. Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evoked by clonidine: A voltammetric approach. J Pharmacol Exp Ther 250:642-647.
194. Touiki K, Rat P, Molimard R, Chait A, de Beaurepaire R. 2005. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl) 182:562-569.
195. Tunnicliff G. 1998. Pharmacology and function of imidazole 4-acetic acid in brain. Gen Pharmacol 31:503-509.
196. Ugedo L, Pineda J, Ruiz-Ortega JA, Martin-Ruiz R. 1998. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: An in vivo and in vitro electrophysiological study. Br J Pharmacol 125:1685-1694.
197. Ugedo L, Pineda J, Martin-Ruiz R, Ruiz-Ortega JA, Artigas F. 1999. Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels. Ann NY Acad Sci 881:365-368.
198. Valentino RJ, Curtis AL. 1991. Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. Prog Brain Res 88:249-256.
199. Van Den Eede F, Van Broeckhoven C, Claes SJ. 2005. Corticotropin- releasing factor-binding protein, stress and major depression. Ageing Res Rev 4:213-239.
200. Wang LG, Gao L, Wang W, Yuan WJ, Wang WZ. 2007. Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats. Neurosci Lett 426:91-96.
201. Welch JE, Saphier D. 1994. Central and peripheral mechanisms in the stimulation of adrenocortical secretion by the 5-hydroxytryptamine2 agonist, (+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. J Pharmacol Exp Ther 270:918-928.
202. Welch JE, Farrar GE, Dunn AJ, Saphier D. 1993. Central 5-HT1A receptors inhibit adrenocortical secretion. Neuroendocrinology 57:272-281.
203. Wenzel RR, Mitchell A, Siffert W, Buhrmann S, Philipp T, Schafers RF. 2004. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br J Clin Pharmacol 57:545-551.
204. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J. 1999. Antiglucocorticoid treatment of depression: Double-blind ketoconazole. Biol Psychiatry 45:1070-1074.
205. Yang YL, Chao PK, Lu KT. 2006. Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 31:912-924.
206. Yehuda R, Yang RK, Buchsbaum MS, Golier JA. 2006. Alterations in cortisol negative feedback inhibition as examined using the ACTH response to cortisol administration in PTSD. Psychoneuroendocrinology 31:447-451.
207. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. 2005. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 30:1719-1723.
208. Zacharko RM, Anisman H. 1991. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci Biobehav Rev 15:391-405.
209. Zeidan MP, Zomkowski AD, Rosa AO, Rodrigues AL, Gabilan NH. 2007. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 565:125-131.
210. Zhang J, Abdel-Rahman AA. 2005. Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension. J Pharmacol Exp Ther 314:945-952.
211. Zhang J, Abdel-Rahman AA. 2006. Nischarin as a functional imidazoline (I1) receptor. FEBS Lett 580:3070-3074.
212. Zhang J, El-Mas MM, Abdel-Rahman AA. 2001. Imidazoline I(1) receptor-induced activation of phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells. Eur J Pharmacol 415:117-125.
213. Zhu H, Halaris A, Piletz JE. 1997a. Chronic imipramine treatment downregulates IR1-imidazoline receptors in rat brainstem. Life Sci 61:1973-1983.
214. Zhu H, Paul IA, McNamara M, Redmond A, Nowak G, Piletz JE. 1997b. Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochem Int 30:101-107.
215. Zhu H, Halaris A, Madakasira S, Pazzaglia P, Goldman N, DeVane CL, Andrew M, Reis D, Piletz JE. 1999. Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients. J Psychiatr Res 33:323-333.
216. Zhu H, Hayes J, Chen M, Baldwin J, Piletz JE. 2003. Relationship between platelet imidazoline receptor-binding peptides and candidate imidazoline-1 receptor, IRAS. Ann NY Acad Sci 1009:439-446.
217. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R12 in major depression: The first 20 patients treated. J Psychiatr Res 34:171-181.
218. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. 2001. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 35:83-94.
219. Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL. 2002. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13:387-391.